Related Experiment Video
Updated: Jun 26, 2026

Identification of Kinesin-1 Cargos Using Fluorescence Microscopy
Published on: February 14, 2016
Kinesin motor proteins as targets for cancer therapy
Dennis Huszar1, Maria-Elena Theoclitou, Jeffrey Skolnik
1Cancer Bioscience, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
Abstract:
The process of mitosis is a validated point of intervention in cancer therapy and a variety of anti-mitotic drugs are successfully being used in the clinic. To date, all approved antimitotics target the spindle microtubules, thus interfering with spindle dynamics, leading to mitotic arrest and apoptosis. While effective, these drugs are also associated with a variety of side effects, including neurotoxicity. In recent years, mitotic kinesins have attracted significant attention in the search for novel, alternative mitotic drug targets. Due to their specific function in mitosis, targeting these proteins creates an opportunity for the development of more selective antimitotics with an improved side effect profile. In addition, kinesin inhibitors may overcome resistance to microtubule targeting drugs. Drug discovery efforts in this area have initially focused on the plus-end directed kinesin spindle protein (KSP) and a variety of compounds are currently undergoing clinical testing.
Insights
Novel anti-mitotic drugs targeting mitotic kinesins offer a promising alternative to current therapies. These new agents aim for greater cancer cell selectivity and reduced side effects compared to existing treatments.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Mitosis is a validated target for cancer therapy, with current drugs acting on spindle microtubules.
- Approved anti-mitotic drugs can cause significant side effects, including neurotoxicity.
- Microtubule-targeting agents may lead to drug resistance.
Purpose of the Study:
- To explore novel therapeutic strategies by targeting mitotic kinesins.
- To develop more selective anti-mitotic drugs with improved side effect profiles.
- To identify potential treatments that overcome resistance to existing therapies.
Main Methods:
- Focus on drug discovery efforts targeting mitotic kinesins.
- Investigate the spindle protein kinesin (KSP) as a primary target.
- Clinical testing of novel kinesin inhibitors.
Main Results:
- Mitotic kinesins represent a promising class of novel anti-mitotic drug targets.
- Kinesin inhibitors offer potential for improved selectivity and reduced toxicity.
- Compounds targeting KSP are advancing through clinical trials.
Conclusions:
- Targeting mitotic kinesins provides a new avenue for cancer therapy development.
- Kinesin inhibitors may offer a more effective and safer alternative to microtubule agents.
- Further research and clinical evaluation of kinesin inhibitors are warranted.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Destabilization of Microtubules
The Movement of Organelles and Vesicles
Microtubule Associated Motor Proteins
Drugs that Stabilize Microtubules
